To advance pharmaceutical education and research in India, an MoU has been signed between National Institute of Pharmaceutical Education and Research (NIPER), Raebareli and Boehringer Ingelheim India.

On the occasion, Cohort 2 of AMRITVA (Alliance for Medicinal Research, Innovation, Translation & Value Acceleration) was also launched to strengthen India’s innovation system and enable translation of research outcomes into viable pharmaceutical products and entrepreneurial ventures.  AMRITVA is implemented by the Startup Incubation and Innovation Centre (SIIC), IIT Kanpur, in partnership with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli. This is an initiative supported under Corporate Social Responsibility (CSR) by Boehringer Ingelheim India.

The MoU was signed in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers in New Delhi.

As part of Cohort 2, five innovators have been selected for grant support aimed at facilitating the commercialization of their research. Financial assistance has been provided to three faculty-led projects and two research scholar-led projects.

The MoU signed between Boehringer Ingelheim India and NIPER Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, academic exchange, and capability-building programmes.

As part of this collaboration, Boehringer Ingelheim will provide access to its opnMe® open science platform to researchers and institutions, enabling scientific exchange and accelerating innovation in healthcare.